Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03324282
Title First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma (GCISAVE)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Bordeaux
Indications

bladder urothelial carcinoma

Therapies

Cisplatin + Gemcitabine

Avelumab + Cisplatin + Gemcitabine

Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.